e-learning
resources
Virtual 2021
05.09.2021
COVID - 19 biomarkers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lymphocyte-to-monocyte ratio (LMR) as a predictor of Covid-19 pneumonia progression
D. Koval (Dnipropetrovsk, Ukraine), T. Pertseva (Dnipropetrovsk, Ukraine), L. Konopkina (Dnipropetrovsk, Ukraine), K. Bielosludtseva (Dnipropetrovsk, Ukraine), M. Krykhtina (Dnipropetrovsk, Ukraine)
Source:
Virtual Congress 2021 – COVID - 19 biomarkers
Session:
COVID - 19 biomarkers
Session type:
E-poster
Number:
651
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Koval (Dnipropetrovsk, Ukraine), T. Pertseva (Dnipropetrovsk, Ukraine), L. Konopkina (Dnipropetrovsk, Ukraine), K. Bielosludtseva (Dnipropetrovsk, Ukraine), M. Krykhtina (Dnipropetrovsk, Ukraine). Lymphocyte-to-monocyte ratio (LMR) as a predictor of Covid-19 pneumonia progression. 651
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Platelet-to-lymphocyte ratio (PLR) as a predictor of Covid-19 pneumonia progression
Source: Virtual Congress 2021 – COVID - 19 biomarkers
Year: 2021
Lymphocyte-to-Monocyte ratio (LMR) and Platelet-to-lymphocyte (PLR) ratio levels as a predictors of lung failure in severe Covid-19 pneumonia patients (pts)
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021
Neutrophil CD64 versus Neutrophil/Lymphocyte ratio (NLR) as markers predicting in-hospital outcome in acute exacerbation of COPD
Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes
Year: 2017
The best predictor of COVID-19 pneumonia progression during lung ultrasound (LUS)
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021
Fibrinogen like the predictor of COVID-19 pneumonia progression
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021
I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP)
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
Prognostic value of haematological markers such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in small cell lung cancer.
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012
Procalcitonin and clinical pulmonary infection score as predictors of stroke associated pneumonia.
Source: International Congress 2018 – Critically ill patients: prognostic factors and biomarkers
Year: 2018
Incidence and etiology of early (E) and late (L) onset ventilator-associated pneumonia (VAP) in a university hospital
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
Community acquired pneumonia (CAP) mortality and biomarkers
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005
Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Community acquired pneumonia (CAP) and PSI mortality risk stratification
Source: Eur Respir J 2004; 24: Suppl. 48, 413s
Year: 2004
The pneumonia severity index (PSI) do not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
The composite physiological index strongly predicts mortality in interstitial lung disease (ILD) associated pulmonary hypertension (PH-ILD)
Source: International Congress 2017 – Imaging and lung disease PH
Year: 2017
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Influence of chronic cardiovascular diseases (CVD) on course and outcome of community-acquired pneumonia (CAP)
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017
The prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with non-small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
Azithromycin (AZM) reduces death or severe respiratory morbidity at 12 month adjusted age (AA) in Ureaplasma-positive intubated preterms.
Source: International Congress 2018 – Prematurity and lung disease
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept